City Therapeutics, a clinical-stage biotechnology company developing RNA interference (RNAi) therapies, raised $200 million in an upsized initial public offering, pricing 11.1 million shares at $18 each. The offering priced at the midpoint of its $17 to $19 range, giving the Cambridge, Massachusetts-based company a fully diluted market valuation of approximately $1.0 billion. The company plans to list on the Nasdaq under the ticker symbol CTY.
Company Background and RNAi Platform
City Therapeutics is developing RNAi-based medicines designed to silence disease-relevant proteins. Its pipeline focuses on conditions with significant unmet medical needs, including thromboembolic diseases, Stargardt disease type 1, and anemia of chronic disease.
The company’s approach uses RNA interference to reduce the production of targeted proteins, offering a potential treatment strategy across several disease areas. As a clinical-stage biotechnology business, City Therapeutics remains focused on advancing its pipeline through clinical development.
Lead Candidate CITY-FXI Advances Into Phase 1
The company’s lead candidate, CITY-FXI, is an engineered, GalNAc-conjugated small interfering RNA (siRNA) therapeutic designed to target Factor XI (FXI), a protein involved in blood clotting.
City Therapeutics initiated a Phase 1 clinical trial for CITY-FXI in 2026, beginning with three single-ascending-dose cohorts involving healthy volunteers. Additional Phase 1 single-ascending-dose data is expected in late 2026, providing a potential milestone for investors monitoring the program’s progress.
The candidate is being developed for thromboembolic diseases, where the company believes its RNAi approach could offer a differentiated treatment option.
IPO Details and Valuation
City Therapeutics raised $200 million through the sale of approximately 11.1 million shares at $18 each. The final offering price landed within the proposed $17 to $19 range, and the transaction valued the company at approximately $1.0 billion on a fully diluted basis.
Goldman Sachs, Jefferies, Stifel, and Oppenheimer & Co. served as joint bookrunners. The company is based in Cambridge, Massachusetts, and will trade on the Nasdaq under the symbol CTY.
Market Opportunities and Risks
City Therapeutics enters the public markets with a pipeline spanning multiple disease areas and a lead candidate already in Phase 1 development. Its RNAi platform may provide opportunities to develop targeted therapies, but the company’s longer-term prospects will depend on clinical results and its ability to advance candidates through subsequent development stages.
As a clinical-stage biotech, City Therapeutics also faces the risks associated with drug development, including uncertain trial outcomes, regulatory requirements, funding needs, and the time required to demonstrate safety and efficacy. The expected late-2026 clinical data update for CITY-FXI represents an important upcoming milestone, although the outcome remains uncertain.
Closing Insights
City Therapeutics’ $200 million IPO provides funding and public-market access as it advances its RNAi pipeline. The $18 offering price and approximately $1.0 billion fully diluted valuation establish its initial public-market benchmark, while progress with CITY-FXI and the company’s broader clinical programs will be central to its future outlook.
